Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

CRESCENT BIOPHARMA, INC. Director's Dealing 2018

May 11, 2018

33678_dirs_2018-05-11_0cd574a3-03a8-442b-9c69-722d221cf65e.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GLYCOMIMETICS INC (GLYC)
CIK: 0001253689
Period of Report: 2018-05-10

Reporting Person: NEW ENTERPRISE ASSOCIATES 10 L P (10% Owner)
Reporting Person: NEA PARTNERS 10 L P (10% Owner)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2018-05-10 Common Stock X 216046 $0.33 Acquired 4706797 Direct
2018-05-10 Common Stock S 4006 $17.81 Disposed 4702791 Direct
2018-05-10 Common Stock X 298406 $0.33 Acquired 5001197 Direct
2018-05-10 Common Stock S 5533 $17.81 Disposed 4995664 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2018-05-10 Warrant to Purchase Common Stock (right to buy) $0.33 X 216046 Disposed 2018-07-03 Common Stock (216046) Direct
2018-05-10 Warrant to Purchase Common Stock (right to buy) $0.33 X 298406 Disposed 2019-01-16 Common Stock (298406) Direct

Footnotes

F1: The shares are directly held by New Enterprise Associates 10, Limited Partnership ("NEA 10") and indirectly held by NEA Partners 10, Limited Partnership ("NEA Partners 10"), the sole general partner of NEA 10, and the individual general partners of NEA Partners 10 (NEA Partners 10 and its individual general partners together, the "Indirect Reporting Persons"). The individual general partners of NEA Partners 10 are Peter J. Barris, M. James Barrett and Scott D. Sandell. Each Indirect Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 10 shares in which such Indirect Reporting Person has no pecuniary interest.

F2: On May 10, 2018, NEA 10 exercised warrants to purchase a total of 216,046 shares of the Issuer's common stock for $0.33 a share. NEA 10 paid the exercise price on a cashless basis, resulting in the Issuer's withholding of 4,006 of the warrant shares to pay the exercise price and issuing 212,040 shares to NEA 10. The Issuer also paid cash to NEA 10 in lieu of any fractional shares to be issued upon exercise of the warrants.

F3: On May 10, 2018, NEA 10 exercised warrants to purchase a total of 298,406 shares of the Issuer's common stock for $0.33 a share. NEA 10 paid the exercise price on a cashless basis, resulting in the Issuer's withholding of 5,533 of the warrant shares to pay the exercise price and issuing 292,873 shares to NEA 10. The Issuer also paid cash to NEA 10 in lieu of any fractional shares to be issued upon exercise of the warrants.